Jun 26 |
Senior VP & Chief Medical Officer of GlycoMimetics Edwin Rock Buys 81% More Shares
|
Jun 21 |
$1M Bet On This Penny Stock? Check Out These 4 Stocks Under $2 Insiders Are Aggressively Buying
|
Jun 4 |
GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
|
May 29 |
GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024
|
May 28 |
Pipeline Moves: Phase III AML trial fails to meet primary endpoint
|
May 10 |
GlycoMimetics GAAP EPS of -$0.17 in-line
|
May 9 |
GlycoMimetics, Inc. (GLYC) Corporate Update Call Transcript
|
May 8 |
GlycoMimetics Q1 2024 Earnings Preview
|
May 8 |
Uproleselan’s failed Phase III AML trial shakes up GlycoMimetics’ future
|
May 7 |
GlycoMimetics reports data from Phase III AML treatment trial
|